- Home
- DT vs PODD Comparison
DT vs PODD Comparison
Compare DT & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DT
- PODD
- Stock Information
- Founded
- DT 2005
- PODD 2000
- Country
- DT United States
- PODD United States
- Employees
- DT N/A
- PODD N/A
- Industry
- DT Computer Software: Prepackaged Software
- PODD Medical/Dental Instruments
- Sector
- DT Technology
- PODD Health Care
- Exchange
- DT Nasdaq
- PODD Nasdaq
- Market Cap
- DT 18.7B
- PODD 19.0B
- IPO Year
- DT 2019
- PODD 2007
- Fundamental
- Price
- DT $52.37
- PODD $251.81
- Analyst Decision
- DT Buy
- PODD Buy
- Analyst Count
- DT 26
- PODD 17
- Target Price
- DT $61.04
- PODD $294.65
- AVG Volume (30 Days)
- DT 2.7M
- PODD 815.4K
- Earning Date
- DT 01-30-2025
- PODD 02-20-2025
- Dividend Yield
- DT N/A
- PODD N/A
- EPS Growth
- DT 143.80
- PODD 96.55
- EPS
- DT 1.60
- PODD 5.78
- Revenue
- DT $1,634,366,000.00
- PODD $2,071,600,000.00
- Revenue This Year
- DT $21.56
- PODD $20.58
- Revenue Next Year
- DT $15.12
- PODD $17.41
- P/E Ratio
- DT $32.62
- PODD $43.53
- Revenue Growth
- DT 19.81
- PODD 22.07
- 52 Week Low
- DT $39.42
- PODD $160.19
- 52 Week High
- DT $63.00
- PODD $289.46
- Technical
- Relative Strength Index (RSI)
- DT 31.46
- PODD 30.78
- Support Level
- DT $53.67
- PODD $261.25
- Resistance Level
- DT $56.33
- PODD $279.64
- Average True Range (ATR)
- DT 1.62
- PODD 10.42
- MACD
- DT -0.94
- PODD -2.86
- Stochastic Oscillator
- DT 3.14
- PODD 12.32
About DT Dynatrace Inc.
Dynatrace is a cloud-native company that focuses on analyzing machine data. Its product portfolio, delivered as software as a service, allows a client to monitor and analyze its entire IT infrastructure. Dynatrace's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to use it for a variety of applications throughout their businesses.
About PODD Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it world-wide.